% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Regnery:163956,
      author       = {S. Regnery and T. Eichkorn and F. Weykamp and T. Held and
                      L.-A. Dinges and F. Schunn and H. Winter and M. Thomas and
                      J. Debus$^*$ and R. A. El Shafie and S. Adeberg and J.
                      Hörner-Rieber$^*$},
      title        = {{P}rogression of {P}ulmonary {F}unction and {C}orrelation
                      with {S}urvival {F}ollowing {S}tereotactic {B}ody
                      {R}adiotherapy of {C}entral and {U}ltracentral {L}ung
                      {T}umors.},
      journal      = {Cancers},
      volume       = {12},
      number       = {10},
      issn         = {2072-6694},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2020-02169},
      pages        = {2862},
      year         = {2020},
      note         = {#LA:E050#},
      abstract     = {Stereotactic body radiotherapy (SBRT) to central and
                      ultracentral lung tumors carries a risk of excessive
                      toxicity. This study analyzed changes in pulmonary function
                      tests (PFT) and their correlation with overall survival (OS)
                      in 107 patients following central (n = 62) or ultracentral
                      (n = 45) lung SBRT. Ultracentral location was defined as
                      planning target volume overlap with the proximal bronchial
                      tree (PBT). Vital capacity (VC) (-0.3 l, absolute $-9.4\%$
                      of predicted, both p < 0.001) and forced expiratory volume
                      in the first second (FEV1s) (-0.2 l, absolute $-7.7\%$ of
                      predicted, both p < 0.001) significantly decreased following
                      SBRT. Higher maximum dose to the PBT significantly
                      correlated with a steeper decline in VC (p = 0.005) and
                      FEV1s (p = 0.03) over time. Pronounced decline in FEV1s
                      between 6 and 12 months (HR = 0.90, p = 0.006) and
                      pronounced decline in VC between baseline and 12 months (HR
                      = 0.95, p = 0.004) independently correlated with worse OS.
                      Consequently, PFT presented a statistically significant
                      albeit clinically mild decrease in lung volumes following
                      central and ultracentral SBRT that correlated moderately
                      with maximum dose to the PBT. Stronger decline in pulmonary
                      function was associated with constrained survival,
                      advocating consequent performance of PFT during follow-up.},
      cin          = {E050},
      ddc          = {610},
      cid          = {I:(DE-He78)E050-20160331},
      pnm          = {315 - Imaging and radiooncology (POF3-315)},
      pid          = {G:(DE-HGF)POF3-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:33027940},
      doi          = {10.3390/cancers12102862},
      url          = {https://inrepo02.dkfz.de/record/163956},
}